Drug Type Bispecific antibody |
Synonyms ZG-005, ZG005 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 2 | CN | 01 Sep 2024 | |
Advanced Neuroendocrine Carcinoma | Phase 2 | CN | 24 May 2024 | |
Advanced Cervical Carcinoma | Phase 2 | CN | 18 Mar 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 15 Jun 2022 | |
Solid tumor | Phase 2 | - | - |
CTR20220021 (NEWS) Manual | Phase 1/2 | 46 | gtkfofhsqy(gpnkqgjibf) = wvxshiapzq peowwxqeyb (wtcqpemwvo ) View more | Positive | 25 Sep 2024 | ||
(20 mg/kg) | gtkfofhsqy(gpnkqgjibf) = losmvzdfqt peowwxqeyb (wtcqpemwvo ) View more | ||||||
Not Applicable | Advanced Hepatocellular Carcinoma First line | 10 | rhamfwdhca(tikumvdjww) = uiocgnmrzr mbadkucmzv (zdescijeqf ) View more | Positive | 25 Sep 2024 | ||
CTR20220021 (ASCO2024) Manual | Phase 1 | 57 | crdvepgkhc(eluihpeezx) = iwgrflyhhx nmspozehcq (tegaowzfni ) View more | Positive | 24 May 2024 | ||
(cervical cancer) | crdvepgkhc(eluihpeezx) = qmiskknstp nmspozehcq (tegaowzfni ) View more | ||||||
CTR20220021 (ASCO2023) Manual | Phase 1 | 16 | flgxnqbsrx(cskpnqhmso) = kcjcnrqmij zvpacjwemp (yewopfooec ) View more | Positive | 26 May 2023 |